Total
0
Shares
Alterity Therapeutics (ASX:ATH) - CEO & Chairman, Geoffrey Kempler - The Market Herald
CEO & Chairman, Geoffrey Kempler
Source: Finance News Network
  • Biotech company Alterity Therapeutics (ATH) has entered back-to-back trading halts as it considers, plans and executes an equity raise
  • The healthcare stock, which is listed on the ASX and the U.S.-based NASDAQ, will keep its shares paused from trade until Friday, October 16
  • At this stage, the details of the raise — and just how much Alterity wants to pocket — remain unclear
  • Alterity is currently working on a suite of treatments to support people with neurodegenerative disorders
  • Alterity shares last traded for five cents each on Friday, October 9

Biotech company Alterity Therapeutics (ATH) has entered back-to-back trading halts as it considers, plans and executes an equity raise.

The healthcare stock, which is listed on the ASX and the U.S.-based NASDAQ, will keep its shares paused from trade until Friday, October 16.

At this stage, the details of the raise — and just how much Alterity wants to pocket — remain unclear. Nevertheless, shareholders should find out more information by the end of the week.

Alterity is currently working on a suite of treatments to support people with neurodegenerative disorders.

Its lead candidate, formally known as ATH434, is currently involved in clinical trials. Previously, the drug has been deemed effective in animal studies against a family of disorders which includes Parkinson's disease.

In Australia, it's estimated that one in 308 people live with Parkinson's. In fact, Parkinson's Australia says 37 new cases are recorded every single day, and the total economic cost of the disease totals just shy of $10 billion every year.

At the end of FY20, Alterity met with the U.S. Food and Drug Administration (FDA) to receive guidance for its ATH434 treatment.

Already, the company has completed a phase one clinical trial, which evaluated the drug's efficacy as a Multiple System Atrophy (MSA) treatment. MSA is part of a family of Parkinsonian disorders, a branch of neurodegenerative diseases which also includes Parkinson's. Now, Alterity is gearing up for a phase two clinical trial, and is working with the FDA to progress its study design.

Alterity shares last traded for five cents each on Friday, October 9.


Find out more about this capital raise


ATH by the numbers
More From The Market Herald
Noxopharm (ASX:NOX) - Executive Chairman & CEO, Graham Kelly - The Market Herald

" Noxopharm (ASX:NOX) enters trading halt ahead of capital raise

Noxopharm (NOX) has entered a trading halt ahead of an upcoming capital raise.
The Food Revolution Group (ASX:FOD) remains open and fully operational

" The Food Revolution Group (ASX:FOD) enters trading halt following Original Juice Co update

The Food Revolution Group (FOD) has entered a trading halt for the purpose of an upcoming capital raise.
Chalice Gold Mines (ASX:CHN) - Managing Director, Alex Dorsch - The Market Herald

" Chalice Gold Mines (ASX:CHN) to raise up to $100M for exploration

Chalice Gold Mines (CHN) has announced it is looking to raise up to $100 million through an institutional placement and share purchase plan.
Davenport Resources (ASX:DAV) enters back-to-back trading halts

" Davenport Resources (ASX:DAV) enters back-to-back trading halts

Davenport Resources (DAV) has entered back-to-back trading halts ahead of an upcoming capital raise.